[1] IIZUKA T, SAKAI F, SUZUKI N, et al.Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome[J].Neurology, 2002, 59(6):816.
[2] PAVLAKIS SG, PHILLIPS PC, DIMAURO S, et al.Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes:a distinctive clinical syndrome[J].Ann Neurol, 1984, 16(4):481.
[3] LIN J, ZHAO CB, LU JH, et al.Novel mutations m.3959G> A and m.3995A> G in mitochondrial gene MT-ND1 associated with MELAS[J].Mitochondrial DNA, 2014, 25(1):56.
[4] GOODFELLOW JA, DANI K, STEWART W, et al.Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes:an important cause of stroke in young people[J].Postgrad Med J, 2012, 88(1040):326.
[5] AMORNVIT J, PASUTHARNCHAT N, PACHINBURAVAN M, et al.Fulminant respiratory muscle paralysis, an expanding clinical spectrum of mitochondrial A3243G tRNALeu mutation[J].J Med Assoc Thai, 2014, 97(4):467.
[6] VAN ADEL BA, TARNOPOLSKY MA.Metabolic myopathies:update 2009[J].J Clin Neuromuscul Dis, 2009, 10(3):97.
[7] FINSTERER J.Chronic anemia as a manifestation of MELAS syndrome[J].Rev Invest Clin, 2011, 63(1):100.
[8] SPROULE DM, KAUFMANN P.Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes[J].Ann N Y Acad Sei, 2008, 1142(1):133.
[9] YATSUGA S, POVALKO N, NISHIOKA J, et al.MELAS:a nationwide prospective cohort study of 96 patients in Japan[J].Biochim Biophy Acta, 2012, 1820(5):619.
[10] SIDDIQ I, WIDJAJA E, TEIN I.Clinical and radiologic reversal of stroke-like episodes in MELAS with high-dose l-arginine[J].Neurology, 2015, 85(2):197.
[11] TSCHAMPA HJ, URBACH H, GRESCHUS S, et al.Neuroimaging characteristics in mitochondrial encephalopathies associated with the m.3243A> G MTTL1 mutation[J].J Neurol, 2013, 260(4):1071.
[12] WEIDUSCHAT N, KAUFMANN P, MAO X, et al.Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers[J].Neurology, 2014, 82(9):798.
[13] IKAWA M, YONEDA M, MURAMATSU T, et al.Detection of preclinically latent hyperperfusion due to stroke-like episodes by arterial spin-labeling perfusion MRI in MELAS patients[J].Mitochondrion, 2013, 13(6):676.
[14] MOTODA A, KURASHIGE T, SUGIURA T, et al.A case of MELAS with G13513A mutation presenting with chronic kidney disease long before stroke-like episodes[J].Clin Neurol, 2012, 53(6):446.
[15] JEPPESEN TD, SCHWARTZ M, HANSEN K, et al.Late onset of stroke-like episode associated with a 3256C→ T point mutation of mitochondrial DNA[J].J Neurol Sci, 2003, 214(1):17.
[16] GOTO M, KOMAKI H, SAITO T, et al.MELAS phenotype associated with m.3302A> G mutation in mitochondrial tRNA Leu (UUR) gene[J].Brain Dev, 2014, 36(2):180.
[17] GLOVER EI, MARTIN J, MAHER A, et al.A randomized trial of coenzyme Q10 in mitochondrial disorders[J].Muscle Nerve, 2010, 42(5):739.
[18] SCAGLIA F, NORTHROP JL.The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome[J].CNS Drugs, 2006, 20(6):443.
[19] EL-HATTAB AW, ADESINA AM, JONES J, et al.MELAS syndrome:Clinical manifestations, pathogenesis, and treatment options[J].Mol Genet Metab, 2015, 116(1):4.
[20] LIU X, LEE N, HAN T, et al.The new antiepileptic drugs (Levetiracetam and Oxcarbazepine) compared with traditional antiepileptic drugs (Carbamazepine and Valproate) in the initial 52 weeks of monotherapy for epilepsy induced by MELAS-an open-label, prospective, randomised controlled multicenter study[J].Neurology, 2013, 80(7 Suppl):203.